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Summary
Porphyromonas gingivalis lipopolysaccharide (LPS) (strain W50) interacts
with Toll-like receptor 2 (TLR-2) leading to cytokine expression and inflam-
mation, and thereby plays a key role in the pathogenesis of periodontal
disease. The aims of this study were to investigate gene expression of key
regulatory mediators of innate immune responses in a human monocytic cell
line (THP-1) to P. gingivalis LPS and to compare these results with those
obtained using the TLR-4 ligand, Escherichia coli LPS. Custom-made Taqman
low-density arrays were used for expression profiling of 45 different cytokine-
related genes. Both types of LPS highly up-regulated interleukin (IL)-1a and
IL-1b, IL-18 receptor (IL-18R), IL-18R accessory protein and IL-1 family
(IL-1F)9. Expression levels of IL-1F6, IL-1F7 and caspase-1 were unaltered by
either LPS. Genes for tumour necrosis factor-a, IL-6, leukaemia inhibitory
factor and IL-32 were also highly induced by both LPS. For a subset of genes,
including CXC chemokine ligand 5 (CXCL5), expression was induced only
by E. coli LPS or was up-regulated more highly by E. coli compared with
P. gingivalis LPS in THP-1 monocytes. A similar expression pattern was also
observed in dendritic cells. Analysis of signalling pathways which lead to
CXCL5 expression indicated that the mechanisms underpinning the differ-
ential responses did not involve the recruitment of different adaptor proteins
by TLR-2 and TLR-4, and therefore occur downstream of the receptor–
adaptor complex. We conclude that differences in signalling pathways acti-
vated by TLR-2 and TLR-4 ligands lead to differential innate immune
responses which may be important in polymicrobial diseases such as peri-
odontal disease.
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Introduction
Porphyromonas gingivalis is a key periodontal pathogen asso-
ciated with the aetiology of periodontal disease [1]. The host
inflammatory response in the periodontal tissues induced by
bacteria and their components present in dental plaque leads
to breakdown of the attachment apparatus between the
tooth and the supporting bone and may result ultimately in
tooth loss [1]. In addition, epidemiological evidence is now
emerging which shows that periodontal disease may be
linked to systemic disorders such atherosclerosis and type 2
diabetes mellitus [2,3].
The innate immune system constitutes the first line of
defence against periodontal pathogens. Monocytes play a
critical part in this response, migrating to sites of infection
and undergoing differentiation into macrophages and den-
dritic cells which are involved in phagocytosis and the
recruitment of the adaptive immune system through antigen
presentation. Toll-like receptors (TLRs) are a major group of
pattern recognition receptors involved in the detection of
bacterial pathogen-associated molecular patterns (PAMPS).
Lipopolysaccharide (LPS) derived from enteric bacteria
such as Escherichia coli binds to TLR-4 leading to activation
of nuclear factor kappa-light-chain-enhancer of activated
B cells (NF-kB) and mitogen-activated protein kinase
(MAPK) pathways and the production of proinflammatory
cytokines [4]. LPS from P. gingivalis is structurally distinct
from other types of LPS, such as E. coli, and has been
shown to interact with both TLR-2 or TLR-4 [5–7]. Highly
purified P. gingivalis LPS was found to contain two related
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but distinct isoforms which differed in the lipid A moieties
[5,7]. Therefore, distinct molecular forms of P. gingivalis LPS
may activate TLR-2 and TLR-4 [5]. LPS from P. gingivalis
strain W50 has been well characterized [8,9] and we have
confirmed that it is a TLR-2-specific ligand (unpublished
data). Interaction between TLRs and their ligands leads to
the recruitment of adaptor proteins to the cytoplasmic
domains of the TLRs [10]. The adaptors MyD88 andMyD88
adaptor-like mediate downstream activation of the NF-kB,
c-Jun N-terminal kinase (JNK) and p38 MAPK intracellu-
lar signalling pathways [11,12]. The MyD88-dependent
pathway can also activate several members of the interferon
regulatory factor (IRF) family of transcription factors,
including IRF5 [10]. MyD88 is utilized by all the TLRs
except TLR-3 to activate intracellular signalling cascades
[13]. TLR-4 can also signal via a MyD88-independent
pathway using the Toll/interleukin (IL)-1 receptor domain-
containing adaptor inducing IFN-g (TRIF) which is
recruited via the TRIF-related adaptor molecule (TRAM)
leading to NF-kB, MAPK and IRF3 activation [14].
Host immune responses mediated through TLRs are
dependent not only upon specific receptors binding but
also on the nature of the receptor–ligand interaction. For
example, fimbriae and LPS from P. gingivalis both interact
with TLR-2; however, human macrophages display differen-
tial gene expression profiles in response to these stimuli
[6,15,16]. Other studies have shown that different structural
components of PAMPS interact with various accessory
proteins modulating the TLR-mediated response [17]. This
upstream mechanism has been demonstrated in monocytes/
macrophages treated with fimbrial peptides. Thus, distinct
fimbral epitopes interact with CD14 or the b-integrin
CD11b/CD18 which results in distinct cytokine expression
profiles [17].
Differential activation of TLRs by PAMPS such as LPS
leads to the activation of different intracellular signalling
pathways, recruitment of transcription factors and the pro-
duction of different repertoires of cytokines and other
inflammatory mediators [15]. In a mixed infection such as
periodontal disease, differential regulation of genes encoding
inflammatory cytokines and associated molecules may have
an impact on disease pathogenesis. The aims of this study
were to investigate the temporal regulation of immunoregu-
latory genes in response to P. gingivalis LPS (a TLR-2 ligand),
to compare gene expression induced by P. gingivalis and E.
coli LPS (a TLR-4 ligand) and to identify genes which were
regulated differentially in response to these PAMPS.
Materials and methods
Reagents
Unless stated otherwise, all laboratory reagents were pur-
chased fromSigma (Poole,UK).P. gingivalisLPS (strainW50)
was a gift from Dr M. Rangarajan, Barts and the London
School of Medicine and Dentistry, London, UK. E. coli LPS
(strain 0111:B4) and monophosphoryl lipid A (MPLA) were
purchased from Invivogen (San Diego, CA, USA). Experi-
ments using HEK-293 cells stably transfected with either
TLR-2 or TLR-4 confirmed that P. gingivalis (strainW50) was
a specific TLR-2 agonist (Jaedicke, unpublished data).
Human monocyte (THP-1) cell culture
Human pro-monocytic THP-1 cells were purchased from the
European Collection of Cell Cultures (Salisbury,Wilts, UK).
Cells were cultured in RPMI-1640 medium, supplemented
with fetal calf serum (FCS) (10% v/v), L-glutamine (2 mM),
penicillin (100 U/ml) and maintained at 37°C and 5% CO2.
Prior to use, 4 ¥ 106 THP-1 cells per well were differentiated
intomonocytes in six-well plates using 0·1 mM1,25dihydrox-
yvitamin D3 (Merck Biosciences, Nottingham, UK) for 24 h
[18]. After 24 h the ability of the cells to adhere to the plastic
tissue culture dish (indicative of differentiation from pro-
monocytes to monocytes) was assessed by microscopy. Cell
viability was assessed by Trypan blue exclusion.
Isolation and culture of peripheral blood monocytes
Buffy coats obtained from the National Blood Service
(Newcastle upon Tyne, UK) were mixed in a 1:1 ratio with
phosphate-buffered saline (PBS)/ethylenediamine tetraacetic
acid (EDTA) (5 mM), then layered on top of an equal volume
of Histopaque (Sigma). Following centrifugation (300 g for
20 min), the buffy coat layer was removed andmixed with an
equal volumeof PBS/EDTA(5 mM).The cellswerepelleted at
300 g (5 min) and the supernatant was discarded. To remove
erythrocyte contamination, cells were resuspended in eryth-
rocyte lysis buffer (150 mMNH4Cl, 10 mMKHCO3, 0·1 mM
EDTA, pH 7·3) for 3 min before quenching in 10 ml PBS for
10 min. Platelets were removed by resuspending the cells in
PBS/EDTA (2 mM) and centrifuged at 300 g for 10 min.
Peripheral blood mononuclear cells within the buffy coat
were counted prior to incubation in six-well plates at 1 ¥ 106
cells/well. Cells were incubated for 12 h in RPMI-1640
medium, the non-adherent cells (lymphocytes) were
removed and the adherent cells were gently washed twice in
media. Fluorescence-activated cell sorting (FACS), using
a CD14/fluorescein isothiocyanate-conjugated antibody,
confirmed that the isolated cells were monocytes (data not
shown). The purity of the monocyte populations was
between 75 and 82% in all experiments.
Differentiation of peripheral blood monocytes into
dendritic cells
Monocyte-derived dendritic cells (MDDCs) were produced
by plating peripheral blood monocytes at 5 ¥ 105 cells/ml
in six-well plates in RPMI-1640 medium supplemented
with IL-4 (50 ng/ml) and granulocyte–macrophage colony-
stimulating factor (GM-CSF) (10 ng/ml) for 7 days [19].
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Differentiation was confirmed by observing morphological
changes using light microscopy. Changes in expression of
CD1a, CD11C, CD14, human leucocyte antigen D-related
and CD83 were measured by FACS to determine the pheno-
type of MDDCs prior to experimentation (data not shown).
Cell stimulation experiments
All assays measuring gene expression or secreted protein
levels were performed following stimulation of cells with
LPS or MPLA. Previous studies have demonstrated that
monocytes are highly responsive to P. gingivalis LPS (strain
W50), and maximal induction of tumour necrosis factor
(TNF)-a expression was observed following treatment with
100 ng/ml P. gingivalis LPS [18,20]. Relevant controls
were also measured in parallel. E. coli, P. gingivalis LPS
(100 ng/ml) or MPLA (1 mg/ml) were used to stimulate
1 ¥ 106 cells/ml or 5 ¥ 105 cells/ml (MDDCs) in six-well
plates for 0·5 to 48 h.
RNA extraction and reverse transcription
Total RNA was isolated from myeloid cells using a RNeasy
Mini Kit (Qiagen, Crawley, UK). The cells were lysed directly
in situ using RLT buffer (Qiagen). RNA was isolated accord-
ing to the manufacturer’s instructions and was eluted in
RNase-free water (30 ml). Total RNA (1 mg) was then reverse
transcribed using random hexamers in 20 ml reactions using
a high capacity cDNA kit (Applied Biosystems, Warrington,
UK) (ABI) according to the manufacturer’s instructions.
Gene expression assays
Custom-made Taqman low-density arrays (TLDAs) (ABI)
were used for expression profiling based on real-time quan-
titative reverse transcription–polymerase chain reaction
(RT–PCR) to compare the gene expression induced by
P. gingivalis or E. coli LPS with unstimulated THP-1
monocytes. These arrays contained predesigned primers and
Taqman probes (FAM™ reporter dye at the 5′ end of each
Taqman®MGB probe and a non-fluorescent quencher at the
3′ end). Each array contained eight sample loading ports and
2·5 ml of each 20 ml cDNA reaction was loaded into each
port. These arrays contained primers and probes for 45 dif-
ferent cytokine-related genes which regulate inflammatory
processes (Table 1). RNA polymerase was used as endog-
enous control. Amplification and real-time analysis of cDNA
samples loaded onto the TLDAs were performed using an
ABI 7900HT real-time PCRmachine. The results were analy-
sed using sds version 2.2 software (ABI). Single-assay
real-time RT–PCR using Taqman primers and probes (ABI)
were performed for CXC chemokine ligand 5 (CXCL5)
(Hs00171085) to confirm the results obtained from the
arrays. RNA polymerase II (Hs00172187_ml) was used as an
endogenous control.
Table 1. Primers and probes for the quantification of gene expression
using Taqman low-density arrays (TLDAs).
Inflammatory mediator
Primers and
probe assay ID
IL-1a (interleukin-1 alpha) Hs00174092_m1
IL-1b (interleukin-1 beta) Hs00174097_m1
IL-Ra (interleukin-1 receptor antagonist) Hs00277299_m1
IL-1R1 (interleukin-1 receptor-1) Hs00168392_m1
IL-1Acp (interleukin-1 accessory protein) Hs00370506_m1
ICE (IL-1 converting enzyme) (caspase-1) Hs00354836_m1
IL-18 (interleukin-18) Hs00155517_m1
IL-18R1 (interleukin-18 receptor) Hs00175381_m1
IL-18Acp (interleukin-1 accessory protein) Hs00187256_m1
IL-1F6 (interleukin-1 family 6) Hs00205367_m1
IL-1F7 (interleukin-1 family 7) Hs00367199_m1
IL-1F8 (interleukin-1 family 8) Hs00758166_m1
IL-1F9 (interleukin-1 family 9) Hs00219742_m1
IL-1F10 (interleukin-1 family 10) Hs00544661_m1
IL-1Rrp2 (IL-1 receptor-related protein 2) Hs00187259_m1
TNF-a (tumour necrosis factor alpha) Hs00174128_m1
TNFRSF1A (TNF alpha receptor superfamily 1A) Hs00236902_m1
TNFRSF1B (TNF alpha receptor superfamily 1B) Hs00153550_m1
TACE (TNF-a converting enzyme) Hs00234221_m1
IL-4 (interleukin-4) Hs00174122_m1
IL-6 (interleukin-6) Hs00174131_m1
OSM (oncostatin M) Hs00171165_m1
LIF (leukaemia inhibitory factor) Hs00171455_m1
OSMR (oncostatin M receptor) Hs00384278_m1
LIFR (leukaemia inhibitory factor receptor) Hs00158730_m1
IL-10 (interleukin 10) Hs00174086_m1
IL-12a (interleukin-12 chain a) Hs00168405_m1
IL-12b (interleukin-12 chain b) Hs00233688_m1
IL-32 (interleukin-32) Hs00170403_m1
GM-CSF (granulocyte macrophage-colony
stimulating factor)
Hs00171266_m1
IFN-g (interferon gamma) Hs00174143_m1
CCL2 (monocyte chemottractant protein 1) Hs00234140_m1
CX3CL1 (fractalkine) Hs00171086_m1
CXCL5 (epithelial-derived neutrophil activating
protein 78) (ENA-78)
Hs00607029_g1
CCL5 (regulation on activation normal T cell
expressed and secreted) (RANTES)
Hs00174575_m1
CXCL8 (IL-8) Hs00174103_m1
CXCL10 Hs00171042_m1
Leptin Hs00174877_m1
LeptinR (leptin receptor) Hs00174497_m1
ADIPOR1 (adiponectin receptor-1) Hs00360422_m1
ADIPOR2 (adiponectin receptor-2) Hs00226105_m1
Visfatin Hs00237184_m1
INSR (insulin receptor) Hs00169631_m1
RAGE (receptor for advanced glycation end
products)
Hs00153957_m1
CD14 Hs00169122_g1
Control genes
GAPDH (glyceraldehyde-3-phosphate-
dehydrogenase)
Hs99999905_m1
18S Hs99999901_s1
RNA pol II Hs00222679_m1
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Measurement of cytokines and chemokines secreted by
myeloid cells
The concentrations of CXCL5, CXCL8, IL-1b and TNF-a in
culture supernatants were measured by enzyme-linked
immunosorbent assay using commercially available kits
(DuoSet; R&D Systems, Abingdon, Oxford, UK). Each
sample was measured in duplicate and results were obtained
from three independent experiments.
Statistical analyses
Statistically significant differences between groups and over
time were assessed using anova with Bonferroni post-hoc
corrections. For non-parametric data, the Kruskal–Wallis
test and Mann–Whitney U-test were used.
Results
Regulation of gene expression by P. gingivalis and
E. coli LPS
The temporal regulation of cytokine-related genes in THP-1
monocytes following treatment with P. gingivalis or E. coli
LPS for 0·5, 2, 6 and 24 h was assessed using TLDA. Fifteen
of the 45 different genes represented on the arrays (Table 1)
were up-regulated by both types of LPS compared with
unstimulated cells. These genes included those encoding
mediators with well-established roles in chronic inflamma-
tion and the pathogenesis of periodontal disease (e.g. IL-1b,
IL-6 and TNF-a) (Table 2). Some of these genes were
up-regulated maximally 2 h after stimulation with LPS, for
example IL-1a, IL-1b, IL-18 receptor (IL-18R) and CXCL8.
Other genes were up-regulated maximally after 6 h, such as
IL-6, IL-10 and CCL2, while IL-32 was expressed most
highly 24 h post-stimulation (Table 2). Eight of the genes
investigated were found to be up-regulated significantly
more highly by E. coli LPS compared with P. gingivalis LPS
(Table 3). These included the IL-1 family cytokine IL-1
family (IL-1F)8, the haematopoietic growth factor GM-CSF
and the chemokines CCL5, CX3CL1 and CXCL5. Some of
these differentially regulated genes were induced most
highly 2 h after stimulation with LPS, for example oncosta-
tin M, while other genes were up-regulated maximally after
6 h (GM-CSF) and 24 h (visfatin) post-stimulation. Eigh-
teen of the genes assessed were expressed but were not regu-
lated by either type of LPS. Of the remaining genes, four
were not expressed constitutively or were not induced in
monocytes (IL-1F10, IL R-related protein 2, IFN-g and
leptin).
Table 2. Immunoregulatory genes that are upregulated by both Porphyromonas gingivalis and Escherichia coli lipopolysaccharide (LPS).
Gene
Fold change Fold change Fold change Fold change
0·5 h 2 h 6 h 24 h
P. gingivalis E. coli P. gingivalis E. coli P. gingivalis E. coli P. gingivalis E. coli
IL-1 family
IL-1a 25·5 9·4 18·6 10·2 1904 624 1443·2 1001·1 78·2 32·2 245·1 49·5 10·6 2·1 41·9 18·5
IL-1b 26·7 17·8 70·3 29·2 470 121 1125·1 894·3 47·0 13·7 472·2 290·2 26·8 12·3 389·2 78·2
IL-18R 0·8 0·4 0·8 0·5 108 90·3 149·2 103·6 99·4 87·7 44·0 26·5 28·8 22·8 74·0 40·6
IL-18Acp 0·4 0·04 0·7 0·3 71·8 29·0 159·5 144·3 26·1 10·7 35·3 21·5 3·7 1·5 7·6 5·1
IL-1F9 1·1 0·3 1·2 0·6 37·1 4·5 62·1 25·9 4·5 2·1 3·2 2·1 2·1 1·1 1·7 0·8
IL-6 family
IL-6 0·2 0·0 1·0 0·2 1325 1009·3 52·2 28·8 12·0 7·5 788·1 442·1 6·3 4·2 135·3 117·1
LIF 2·1 1·0 0·8 0·3 293·1 218·4 607·4 546·1 3·8 3·0 12·9 8·3 2·6 1·9 13·1 0·6
TNF family
TNF-a 20·1 13·4 41·7 12·5 77·8 30·9 109·3 82·1 2·3 0·9 6·2 1·7 1·2 0·6 2·6 0·5
TNFRSF1B 0·7 0·2 0·7 0·3 0·3 0·1 2·7 2·2 1·1 0·2 3·7 0·8 2·4 0·1 8·5 1·8
Chemokines
CCL2 2·3 1·1 1·9 0·7 26·9 14·5 8·6 5·0 129·1 72·3 56·3 20·7 89·8 47·2 21·0 18·2
CXCL8 7·8 4·7 13·2 4·9 20·9 4·8 43·0 33·0 4·8 2·4 17·7 6·3 2·3 0·9 6·9 1·1
CXCL10 13·06·1 14·711·4 469·5160·1 73·445·4 24761566 503·337·5 1086·1736·0 93·577·9
Other cytokines
IL-10 1·3 0·6 1·1 0·32 7·5 2·8 2·9 0·7 4·4 0·4 27·7 11·9 3·8 0·5 13·3 1·8
IL-12B 2·6 1·6 2·6 0·9 794·2 541·1 570·2 288 137·0 17·3 686·1 157·3 9·1 5·1 127·3 118·0
IL-32 1·0 0·7 1·5 0·7 48·5 22·2 40·0 17·7 67·1 35·3 118·0 55·2 433·5 56·7 247·2 145·1
THP-1monocytes were treated with LPS (100 ng/ml) from either P. gingivalis or E. coli for the times indicated above. Gene expression was quantified
using Taqman low-density arrays by real-time polymerase chain reaction and normalized to RNA polymerase II. The values shown are the mean
fold change compared with untreated cells standard deviation. These results were obtained from three independent experiments. IL, interleukin;
TNF, tumour necrosis factor; TNFRSF1B, TNF alpha receptor superfamily 1B; LIF, leukaemia inhibitory factor.
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The CXCL5 is regulated differentially by P. gingivalis
and E. coli LPS
The array data showed that the chemokine CXCL5 was
up-regulated more highly by LPS from E. coli than P. gin-
givalis (Table 3). This pattern of expression emerged 6 h
post-stimulation with LPS (Table 3). Single-assay real-time
PCR confirmed the data obtained from the TLDAs
(Fig. 1a). Secreted protein levels of CXCL5 were also mea-
sured and showed a similar pattern of regulation by LPS
(Fig. 1b). At both the mRNA and protein levels, significant
differences in CXCL5 expression were detected 48 h post-
stimulation (Fig. 1a and b). These data were obtained using
the human THP-1 monocytic cell line. Therefore, further
experiments were performed to establish whether similar
expression patterns were observed for CXCL5 expression in
primary cells. Primary human monocytes were treated with
LPS from either P. gingivalis or E. coli for 3–48 h. The
untreated cells secreted high levels of CXCL5 (Fig. 1c), and
these levels were increased in monocytes treated with P. gin-
givalis and E. coli LPS. Following 24 h of treatment with E.
coli LPS, there was a significant increase in CXCL5 levels
compared with CXCL5 levels from monocytes treated with
P. gingivalis LPS or the untreated control cells. MDDCs also
expressed CXCL5 constitutively (Fig. 1d) and secreted levels
of this cytokine were up-regulated significantly by E. coli
Table 3. Escherichia coli lipopolysaccharide (LPS) upregulates differentially a subset of genes compared with Porphyromonas gingivalis LPS.
Gene
Fold change Fold change Fold change Fold change
0·5 h 2 h 6 h 24 h
P. gingivalis E. coli P. gingivalis E. coli P. gingivalis E. coli P. gingivalis E. coli
IL-1 family
IL-1F8 0·0 0·0 2·7 1·1 0·0 0·0 3·8 0·8 0·8 0·0 1·7 0·7 0·0 0 101·1 62·0
IL-6 family
OSM 3·0 2·0 3·4 1·5 0·9 0·2 8·2 5·9 0·1 0·0 0·2 0·1 0·1 0·1 1·7 0·9
OSMR 0·3 0·1 0·5 0·2 0·3 0·0 6·4 4·6 0·8 0·3 5·5 1·2 2·8 1·4 8·0 2·4
Chemokines
CCL5 0·6 0·2 0·7 0·1 1·3 0·2 11·6 8·3 1·2 0·2 9·7 4·3 2·7 0·7 10·4 3·8
CXCL5 0·0 0·0 0·0 0·0 1·0 0·0 1·0 0·0 1·2 0·2 6·3 2·1 1·0 0 27·5 5·1
CX3CL1 0·0 0·0 0·0 0·0 2·0 0·4 35·6 17·0 2·1 0·3 3·9 0·6 0·0 0 0·0 0·0
Other cytokines
GM-CSF 0·0 0·0 0·0 0·0 12·9 7·6 58·1 6·5 2·4 1·3 161 52·1 3·0 1·0 105·2 68·8
PBEF/visfatin 0·6 0·2 0·8 0·1 1·3 0·3 2·2 0·4 1·6 0·5 5·1 2·3 2·3 0·6 15·2 4·2
THP-1monocytes were treated with LPS (100 ng/ml) from either P. gingivalis or E. coli for the times indicated above. Gene expression was quantified
using Taqman low-density arrays by real-time polymerase chain reaction. The values shown are the mean fold change compared with untreated
cells standard deviation. These results were obtained from three independent experiments. IL, interleukin; OSM, oncostatin M; OSMR, oncostatin M
receptor; GM-CSF, granulocyte–macrophage colony-stimulating factor; PBEF, pre-B cell colony-enhancing factor.
Fig. 1. CXCL5 is differentially regulated by
Porphyromonas gingivalis and Escherichia coli
lipopolysaccharide (LPS) in myeloid cells. (a)
Real-time reverse transcription–polymerase
chain reaction analysis of CXCL5 expression
using cDNA derived from THP-1 monocytes.
Cells were treated with E. coli LPS (100 ng/ml)
or P. gingivalis LPS (100 ng/ml) until the
indicated time-points. Enzyme-linked
immunosorbent assay was used to measure
secreted CXCL5 in culture supernatants from
(b) THP-1 monocytes, (c) peripheral blood
monocytes and (d) monocyte-derived dendritic
cells. The results were obtained from three
independent experiments and are presented as
average standard deviation.
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LPS compared with P. gingivalis LPS and untreated controls
(48 h).
The CXCL5 secretion does not occur via an IL-1b- or
TNF-a-dependent mechanism
The differential regulation of CXCL5 in myeloid cells
occurs relatively late (24–48 h) compared with other cyto-
kines; for example, CCL5 is expressed maximally 2 h post-
stimulation. It is possible that this effect may not be a direct
result of TLR stimulation but may occur indirectly through
induction of other proinflammatory cytokines. Previously,
IL-1b and TNF-a have been shown to regulate CXCL5
expression in the A459 pulmonary epithelial cell line [21].
The TLDA data show that both IL-1b and TNF-a were
up-regulated highly by both P. gingivalis and E. coli LPS at
the mRNA level (Fig. 2a and c). Real-time PCR showed that
after 24 h, IL-1b levels induced by E. coli LPS were higher
than those induced by P. gingivalis LPS. Secreted IL-1b and
TNF-a were both present in the culture supernatants taken
from cells treated with both types of LPS (Fig. 2b and d).
However, there was no significant difference in the levels of
these cytokines produced in response to either P. gingivalis
or E. coli LPS. When THP-1 monocytes were treated with
IL-1b (250 pg/ml) or TNF-a (500 pg/ml), no secreted
CXCL5 was detected. However, CXCL8 was detected in the
same culture supernatants (data not shown), demonstrating
that the THP-1 monocytes were responsive to both IL-1b
and TNF-a and were incapable of specifically inducing
CXCL5 expression.
Regulation of CXCL5 by other TLR ligands
The MPLA is a TLR-4 agonist but studies in mice have dem-
onstrated that this agonist functions with a bias towards
the use of the TRIF adaptor [22] and therefore utilizing
principally the TRIF–TRAM MyD88-independent pathway.
Although TRIF–TRAM mediates TLR-4 signalling it is not
involved in TLR-2-mediated gene expression [10]. To inves-
tigate if the differential pattern of expression of CXCL5 was
mediated via the TRIF adaptor, THP-1 monocytes were
treated with either MPLA (1 mg/ml) or E. coli LPS (100 ng/
ml) for 48 h, as this was the time at which maximal CXCL5
expression was detected in the previous experiments and at
which point differences in expression levels of CXCL5 fol-
lowing P. gingivalis and E. coli LPS stimulation reached sig-
nificant levels. MPLA did not induce CXCL5 secretion,
although it was induced by two different preparations of E.
coli LPS (Fig. 3a). However,MPLA induced TNF-a secretion
at a similar level to E. coli LPS (Fig. 3b) in the same tissue
culture supernatants in which CXCL5 levels were measured,
indicating that the TRIF–TRAM adaptors are not required
for TLR-4-driven CXCL5 in THP-1 monocytes.
Discussion
This study was undertaken to investigate gene expression in
monocytes following exposure to PAMPS which exert their
effects via TLR-2 and TLR-4, and our data significantly
extend current understanding of cytokine responses by
monocytes following exposure to LPS. In addition, new data
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Fig. 2. Porphyromonas gingivalis and Escherichia coli lipopolysaccharide (LPS) up-regulate interleukin (IL)-1b and tumour necrosis factor (TNF)-a
(a,c) Real-time reverse transcription–polymerase chain reaction was used to quantify IL-1b and TNF-a using Taqman low-density arrays with
cDNA derived from THP-1 cells treated with either P. gingivalis or E. coli LPS. The results were normalized to RNA polymerase II and calculated as
a fold change compared with results obtained from unstimulated cells. (b,d) IL-1b and TNF-a levels in culture supernatant from the THP-1 cells
treated with either P. gingivalis or E. coli LPS, measured by enzyme-linked immunosorbent assay. The results were obtained from three independent
experiments and are presented as average standard deviation.
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are presented which reveal co-ordinate and temporal gene
expression of key inflammatory mediators in response to
LPS from P. gingivalis, an important pathogen associated
with chronic periodontitis. Furthermore, our results show
that P. gingivalis and E. coli LPS have differential effects at the
molecular level, leading to quantitative differences in gene
expression for a subset of cytokine-related genes.
The IL-1 family cytokines have been shown to play an
important role in a variety of chronic inflammatory diseases,
including periodontitis and rheumatoid arthritis [23,24].
Thus, in periodontitis, IL-1b and IL-18 levels in gingival
crevicular fluid correlate with severity of disease [18]. Both
types of LPS up-regulated IL-1a, IL-1b, IL-18R, IL-18 R
accessory protein (IL-18RAcp) and IL-1F9. Interestingly,
certain members of the IL-1 cytokine family such as IL-18,
IL-1R, IL-1RAcp and IL-1Ra were not regulated by LPS at the
mRNA level. Previously, IL-18 mRNA has been shown to be
expressed constitutively in peripheral blood mononuclear
cells; however, stimuli such as LPS up-regulate IL-18 secre-
tion [25]. Furthermore, work from our own laboratory has
shown that P. gingivalis LPS stimulates IL-18 secretion in
monocytes [20,26]. These data emphasize the importance of
post-translational mechanisms of cytokine secretion and
therefore, although analysis of mRNA expression demon-
strates differential cytokine regulation by LPS from different
species of bacteria, further differences may be revealed from
proteomic analysis.
Both types of LPS significantly up-regulated IL-32 expres-
sion compared with the unstimulated cells. This cytokine has
been detected in epithelial cells, natural killer cells and T cells
and possesses proinflammatory properties such the ability to
induce IL-8 and TNF-a [27]. Recently, it has also been
reported that IL-32 is expressed by an oral epithelial cell line
(H400) in response to LPS from the periodontal pathogens
P. gingivalis and F. nucleatum [28]. These data, together with
the finding that IL-32 plays a role in other inflammatory
diseases [29,30] and its ability to induce monocyte differen-
tiation [31], suggest that this cytokine may also contribute to
the pathogenesis of periodontal disease. Therefore, investi-
gation into the role of this cytokine in periodontitis could
provide further understanding of how cytokine networks
function in this disease.
Previous research has shown that different types of E. coli
LPS, acting through TLR-4, induce distinct but overlapping
gene expression profiles [32]. Consistent with our findings,
chemokines were among the genes which were regulated
differentially by LPS [32]. CXCL5 and CXCL8 are both
neutrophil chemoattractants and potent angiogenic factors
[33,34] These chemokines act through the same receptor
(CXCR2) [35] and are produced concomitantly in response
to IL-1b and TNF-a in pulmonary epithelial cells (A459)
[21]. The data from our study show that CXCL8 was
up-regulated by both types of LPS, while CXCL5 was
up-regulated significantly only by E. coli LPS at the mRNA
and protein level in both monocytes and dendritic cells.
Secretion of CXCL5 following LPS stimulation is a relatively
late event (24+ h) compared with other cytokines and there-
fore may be mediated by other proinflammatory cytokines.
In the A459 cell line, which are pulmonary-derived epithelial
cells, both IL-1b and TNF-a were shown to regulate CXCL5
transcription [21]. In our study, both IL-1b and TNF-a were
up-regulated by LPS in monocytes at the mRNA level and
were detected in culture supernatants from LPS-treated cells.
However, when THP-1 monocytes were treated with either
IL-1b or TNF-a at comparable concentrations to those that
were recorded in the supernatants no secreted CXCL5 was
detected, although CXCL8 levels were up-regulated by both
cytokines. This discrepancy, with respect to previous data
obtained in pulmonary epithelial cells, may be due to the
differences in cytokine concentrations used. In our study,
cells were stimulated with either 250 pg/ml or 500 pg/ml of
IL-1b or TNF-a, whereas the pulmonary epithelial cells were
treated with 10–20 ng/ml of IL-1b and TNF-a [21]. The
differences may be due to differential responses to these
cytokines by monocytes and pulmonary epithelial cells.
Although IL-1b and TNF-a are not responsible for TLR-
mediated CXCL5 expression, we cannot rule out the possi-
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were obtained from three independent experiments and represent
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bility that this effect is mediated by other proinflammatory
cytokines. Studies carried out in fibroblasts with an inactive
transforming growth factor-b kinase 1 (TAK1) revealed that
CXCL5 belonged to a group of chemokine genes whose
expression was suppressed most strongly by this inactive
kinase [36]. Furthermore, in fibroblasts CXCL5 expression
was shown to be predominantly mediated by the NF-kB and
JNK pathways [36].
The MPLA is a derivative of LPS and is a TLR-4 agonist
which is associated with a bias for TRIF signalling [22].
TLR-4 activation occurs via the adaptors MyD88 and TRIF,
whereas TLR-2 utilizes only MyD88 [14,16]. Therefore,
THP-1 monocytes were treated with MPLA to investigate
whether the differential expression induced by E. coli LPS
compared with P. gingivalis LPS is due to the recruitment of
TRIF to TLR-4 by E. coli LPS. The results showed that CXCL5
was not expressed in response to MPLA. However, TNF-a
was produced at similar levels to those induced by E. coli LPS,
indicating that the selective use of TRIF adaptor by TLR-4
was not the mechanism by which E. coli LPS up-regulated
CXCL5.
Other cytokines were also expressed differentially in
response to P. gingivalis and E. coli LPS. For some of these
genes, differential regulation occurred at an earlier time-
point compared with CXCL5. For example, regarding the
oncostatin M receptor and GM-CSF, differential regulation
was observed 2 h post-stimulation with LPS. Therefore, this
points to multiple mechanisms contributing to differential
expression in response to these different PAMPS. The data
presented here confirm and extend previous information on
the effects of different PAMPS onmonocytes.Understanding
the mechanisms involved in differential responses will be
important in deciphering pathogen–host interactions and
how these can be manipulated to prevent tissue destruction
associated with chronic inflammatory disease.
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